LOGIN
ID
PW
MemberShip
2025-02-07 05:14
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
InterView
"High hopes for reimbursed Ilaris¡¦a new treatment option"
by
Whang, byung-woo
Feb 5, 2025 05:52am
The Hereditary Periodic Fever (HPF) syndromes cause not just fever and pain but affect various aspects, such as patient's growth and development, psychological elements. The reimbursement coverage of a new treatment in nine years has increased patient satisfaction." Clinical practices have high hopes for changes to the treatment setting as Il
InterView
Approval called for drug switching in atopic dermatitis
by
Whang, byung-woo
Jan 24, 2025 05:51am
Atopic dermatitis treatment settings are changing quickly. New treatment options are available as new drugs with fewer side effects and superior treatment effectiveness than existing therapies emerge. There is a growing interest in how atopic dermatitis can be treated rather than just treating it, as changes have been brought to the treatment
InterView
"Reimb granted to drug switching between JAK inhibitors"
by
Son, Hyung Min
Dec 26, 2024 05:50am
"Until now, drug switching between JAK inhibitors has not been reimbursed, so there have been unmet patient needs for rheumatoid arthritis patients who do not benefit from conventional biological agents. As reimbursement for drug switching will be granted starting in December, patients will be less burdened by switching from biological agent
InterView
¡®New start at a law firm¡¦will become a trusted expert¡¯
by
Kim, Jin-Gu
Dec 13, 2024 05:52am
The role of law firms has greatly expanded in the pharmaceutical bio and healthcare sectors recently. Whereas law firms used to provide piecemeal legal services in the past, law firms have now been providing comprehensive services over a long period of time, covering the whole course of a drug¡¯s journey from pre-approval to reimbursement.
InterView
¡®3 IBD treatment trends¡¦early treatment is the first¡¯
by
Kim, Jin-Gu
Dec 2, 2024 05:49am
The treatment method for a single disease can continue to change at a very fast pace. This is true for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease. In recent years, a variety of drugs have been developed to treat these diseases, and the treatment trend is changing as more research is conducted. Dr. Ju
InterView
¡®Improve new drug access to treat rheumatoid arthritis'
by
Son, Hyung Min
Nov 21, 2024 05:46am
¡°Rheumatoid arthritis is not just a painful disease, but a disease that can cause direct damage to the joints. Patients need to start treatment with good treatments in a timely manner, but their access to new drugs is still limited. Switching between JAK inhibitors should be allowed freely so patients can receive personalized treatment.¡±
InterView
'Early detection of RA can help prevent severe symptoms'
by
Whang, byung-woo
Nov 14, 2024 05:51am
"Rheumatoid arthritis not only induces permanent joint deformities and damages but also has a detrimental effect on quality of life due to many general symptoms. As effective disease management becomes possible following the recent introduction of various treatment options, early diagnosis and patient-customized treatment approach are crucial."
InterView
"Recruiting a company to co-develop pitavastatin+ezetimibe"
by
Kim, Jin-Gu
Oct 30, 2024 05:54am
Shinil Pharmaceutical will collaborate with other biopharmaceutical company to co-develop a generic 'pitavastatin+ezetimibe' combination drug for treating hyperlipidemia. Through joint-collaboration, Shinil Pharmaceutical plans to improve not only the contract manufacturing of medicines but also cost savings and productivity. In the mean
InterView
"JAK inhibitors bring a paradigm shift to RA treatment"
by
Whang, byung-woo
Oct 16, 2024 05:50am
As patients with autoimmune diseases, including rheumatoid arthritis, have better access to medical care, early diagnosis and treatment have been pointed out as the key. Early diagnosis and treatments previously available in university hospitals are now possible in local clinics. As a result, patient-personalized therapies, even for patients
InterView
"An OTC drug increases lymphedema patient satisfaction"
by
Kim, Jin-Gu
Sep 23, 2024 05:50am
Lymphedema occurs when the body's flow of lymph fluid is disrupted. Due to a particular reason, the build-up of lymph fluid between cells causes swelling and hardening of fatty tissues in the arms and legs. Unfortunately, the number of medicines for treating lymphedema is limited. Therefore, there are unmet needs in clinical practices. Hence
1
2
3
4
5
6
7
8
9
10
>